
Featuring a presentation by Dr Matthew Matasar, including the following topics:Selection of First-Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) (0:00)Clinician Survey Results Regarding First-Line Treatment of DLBCL (11:41)Current and Future Roles of Monoclonal and Bispecific Antibodies in Therapy for Relapsed/Refractory (R/R) DLBCL (16:01)Clinician Survey Results Regarding the Use of Monoclonal and Bispecific Antibodies for R/R DLBCL (28:47)Evidence-Based Incorporation of Antibody-Drug Conjugates (ADCs) into the Management of R/R DLBCL (34:34)Clinician Survey Results Regarding the Use of ADCs for R/R DLBCL (46:31)Discussion of Questions from the Community (50:20)CME information and select publications
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

Novel Therapies for Non-Hodgkin Lymphoma — Microlearning Activity 3: An Interview with Dr Matthew Lunning on the Utility of Tafasitamab

Follicular Lymphoma — Where We Are, Where We're Headed in the Use of Bispecific Antibodies

Relapsed/Refractory Multiple Myeloma — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute

Prostate Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute
Free AI-powered recaps of Oncology Today with Dr Neil Love and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.